Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination in First-Line Unresectable or Metastatic Melanoma
UPDATE - Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
Otarmeni Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Dupixent® Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis Phase 3 Trial
Dupixent® Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Providence Gold Reports Up to 8.0 g/t Au from Mojave Girl Phase 2 Evaluation of Tarantula Gold Mine Set to Begin
Metals Australia Limited Announces Participation in THE Mining Investment Event, Quebec City, June 2-4, 2026
